Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

2019

Background Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood.

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

20

References

55

Citations